The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
OsterborgA., DyerM.J.S., BunjesD.Phase II multicenter study of human CD52 antibody in previously treated chronic lym-phocytic leukemia. J Clin Oncol.1997; 5(4): 1567–74.
3.
LundinJ., OsterborgA., BrittingerG.Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. J Clin Oncol.1998; 16(10): 3257–63.
4.
FerrajoliA., O'BrienS., KurzrockR.Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD52 [abstract]. Proc Am Soc Clin Oncol.2000; 19: 8a.
5.
PawsonR., DyerM.J., BargeR.Treatment of T-cell prolym-phocytic leukemia with human CD52 antibody. J Clin Oncol.1997; 15(7): 2667–72.
6.
OsterborgA., FassasA.S., AnagnostopoulosA.Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Hematol.1996; 93(1): 151–3.
7.
ZhangP.The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents.1999; 13(4): 195–200.
8.
NiuC., YanH., TingY.Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood.1999; 94(10): 3315–24.
9.
ShenZ.X., ChenG.Q., NiJ.H.Use of arsenic trioxide (As2O3) in the treatment of acute promelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood.1997; 89(9): 3354–60.
10.
SoignetS., BienvenuB., CheungN.Clinical and pharmaco-logic study of arsenic trioxide (As2O3) in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol.2000; 19: 201a.
11.
DrukerB.J., SawyersC.L., KantarjianH.Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Eng J Med.2001; 344(14): 1038–42.
12.
DrukerB.J., TalpazM., RestaD.J.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med.2001; 344(14): 1031–7.
